Skip Navigation

After 60 years, scientists uncover how thalidomide produced birth defects

  • Defects linked to disruption of key protein involved in fetal development
  • Finding will help guide development of new drugs

More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?

The answer, published online today by the journal Elife, not only helps resolve an issue that has been the subject of scientific curiosity for two generations, but will be critical as pharmaceutical companies develop a promising new generation of anticancer drugs that share a basic chemical architecture with thalidomide, the study authors say.

Building on years of previous research, the researchers found that thalidomide acts by promoting the degradation of an unexpectedly wide range of transcription factors – cell proteins that help switch genes on or off – including one called SALL4. The result is the complete removal of SALL4 from cells.

The degradation of SALL4 interferes with limb development and other aspects of fetal growth. The result is the spectrum of complications indelibly linked to thalidomide: the deformed limbs and defective organs in children whose mothers took thalidomide during pregnancy as a treatment for morning sickness.

Support for these findings came from reports in medical literature. Individuals who carry a mutation in the gene for SALL4 are often born with missing thumbs, underdeveloped limbs, eye and ear defects, and congenital heart disease – problems which mirror those in children exposed to thalidomide in the womb.

"The similarities between the birth defects associated with thalidomide and those in people with a mutated SALL4 gene are striking," says the new study's senior author, Eric Fischer, PhD, of Dana-Farber. "They make the case even more strongly that disruption of SALL4 is at the root of the devastation produced by thalidomide in the 1950s."

The findings are apt to mark an important inflection point in the history of thalidomide, a drug more infamous than famous. Marketed and sold extensively in Europe, Australia, and some South American countries – though never approved in the United States – as a treatment for pregnancy-related morning sickness, it became a source of anguish when it became clear that it was responsible for birth defects in more than 10,000 children and an unknown number of miscarriages. The medical community was slow to discover the danger of thalidomide because the drug gave rise to birth defects only when taken between the fourth and eighth weeks of pregnancy.  It was officially banned in 1961.

In the 1980s, thalidomide gained a second life when it was found to be a powerful anti-angiogenic drug, inhibiting the growth of blood vessels in tumors. As such, it has come into wide use as a cancer drug, primarily in the treatment of multiple myeloma. 

Knowing the mechanism by which thalidomide produces birth defects will be critical as drug developers devise and test new drugs that use the same structural "scaffold" as thalidomide, Fischer remarks. "As new derivatives are tested, we'll be able to explore whether they have the same potentially damaging effects as thalidomide. We know that the therapeutic effect of these drugs is based on their ability to degrade specific proteins.  Our findings will help drug developers distinguish between proteins whose degradation is likely to be beneficial and whose may be harmful."

The lead author of the Elife study is Katherine A. Donovan, of Dana-Farber.  Co-authors are Jian An, PhD, Radoslaw P. Nowak, Jingting C. Yuan, of Dana-Farber; and Emma C. Fink, Bethany Berry, Benjamin L. Ebert, MD, PhD, of Dana-Farber and Brigham and women's Hospital.

Financial support for the research was provided by the National Institutes of Health (grant NCI R01CA214608), the Novartis/Dana-Farber Drug Discovery Program, the Friends of Dana-Farber, and the Linde Family Foundation.

Study link: https://doi.org/10.7554/eLife.38430.

 

 

Posted on August 01, 2018

  • Research
  • Eric Fischer, PhD
  • Multiple Myeloma

Media Contacts

For all inquiries, call 617-632-4090 and ask to speak to a member of the media team. Please direct emails to media@dfci.harvard.edu.

Thalidomide molecule

Eric Fischer, Dana-Farber Cancer Institute